🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Immunotherapy

Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347NA1 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: anlotinib+bevacizumab Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) NCT07165847Phase 21 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur, Radiotherapy Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence NCT06954116Phase 21 site📍 Wuhan Tongji Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), Partial hepatectomy VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma NCT03556228Phase 1, Phase 215 sites📍 Santa Rosa📍 Hartford📍 Washington D.C. VM Oncology, LLC · Tests: VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer NCT06121700Phase 21 site📍 Shanghai Fudan University · Tests: Radiotherapy targeted to the primary lesion, Radiotherapy targeted to the metastatic lesions, Anti-PD-1 monoclonal anti… Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance NCT06483100Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Elrantamab, clonoSEQ Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor. NCT07754409n/a1 site📍 Gothenburg Göteborg University Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106Phase 31 site📍 Beijing Shanghai Kechow Pharma, Inc. · Tests: tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer NCT06928584Phase 21 site📍 Shanghai Fudan University · Tests: Conventional Radiotherapy, Capecitabine, 5-fluorouracil, folinic acid, Oxaliplatin Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma NCT05937438Phase 1, Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Immune Checkpoint Inhibitors Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma NCT05595408n/a1 site📍 Shanghai RenJi Hospital · Tests: Adjuvant chemotherapy, adjuvant immunotherapy Naltrexone and Propranolol Combined With Immunotherapy NCT05968690Phase 11 site📍 New Brunswick Sarah Weiss · Tests: Propranolol, Naltrexone A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites📍 Duarte📍 La Jolla📍 Ann Arbor Incyte Corporation · Tests: INCA036873 Timing of Immunotherapy in Melanoma NCT07696715NA5 sites📍 Amsterdam📍 Amsterdam📍 Leiden Radboud University Medical Center · Tests: Timing of first administration (early morning), Timing of immunotherapy (afternoon) NK Cell Therapy for Malignant Solid Brain Tumors NCT07552233NA4 sites📍 Beijing📍 Qinhuangdao📍 Zhengzhou Peking University Third Hospital · Tests: Autologous NK cells A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma NCT06843889Phase 21 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: Toripalimab (240mg day1, Q3W*3cycle) A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE NCT03989323n/a5 sites📍 Bron📍 Bron📍 Lyon Hospices Civils de Lyon · Tests: Estimation of the incidence of the irAE rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG NCT04943848Phase 13 sites📍 Orange📍 Chicago📍 Boston Ann & Robert H Lurie Children's Hospital of Chicago · Tests: rHSC-DIPGVax, Balstilimab, Zalifrelimab Plasmodium Immunotherapy for Advanced Malignant Solid Tumors NCT04165590Phase 1, Phase 21 site📍 Kunming CAS Lamvac Biotech Co., Ltd. · Tests: Plasmodium immunotherapy Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer NCT04992780Phase 26 sites📍 Kansas City📍 Overland Park📍 Topeka University of Kansas Medical Center · Tests: Hypo-Fractionation, Standard-Fractionation Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients NCT06261554NA1 site📍 Warsaw Medical University of Warsaw · Tests: Dietary Supplement: Low dose OIT DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer NCT07545954Phase 11 site📍 St Louis Washington University School of Medicine · Tests: DSP-0390, Atezolizumab A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) NCT05657873Phase 29 sites📍 Miami📍 Basking Ridge📍 Middletown Memorial Sloan Kettering Cancer Center · Tests: L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer NCT02133196Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Aldesleukin, Fludarabine, Cyclophosphamide, Young TIL Feasibility of a Lifestyle Intervention for Women With Triple-negative Breast Cancer Under Neoadjuvant Immunotherapy NCT07311083NA1 site📍 Essen Kliniken Essen-Mitte · Tests: switching to a high-fibre diet, official dietary recommendations D2C7-IT + 2141-V11 Combination Post-resection in rGBM NCT06455605Phase 11 site📍 Durham Darell Bigner · Tests: D2C7-IT, 2141 V11 Single cEll pRofiling PErsistaNce To ImmuNothErapy NCT06680739Phase 21 site📍 Barcelona Vall d'Hebron Institute of Oncology · Tests: Durvalumab, Tremelimumab Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer NCT07315854Phase 21 site📍 Beijing Beijing Friendship Hospital · Tests: Iparomlimab and Tuvonralimab (QL1706), SOX Chemotherapy Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial NCT06841705Phase 22 sites📍 Boston📍 Boston Shilpa Grover, MD, MPH · Tests: Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper, Placebo Prednisone Capsu… DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER NCT07690540NA1 site📍 Milan European Institute of Oncology · Tests: Prospective exploratory cohort
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy